Tempus AI (NASDAQ:TEM) Trading Up 3.8% – Should You Buy?

Shares of Tempus AI, Inc. (NASDAQ:TEM) shot up 3.8% during mid-day trading on Thursday . The stock traded as high as $35.29 and last traded at $35.05. 1,233,969 shares traded hands during trading, a decline of 25% from the average session volume of 1,636,523 shares. The stock had previously closed at $33.76.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on TEM. Wolfe Research initiated coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Loop Capital increased their target price on Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, October 15th. Piper Sandler reiterated a “neutral” rating and set a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Bank of America increased their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Finally, Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and boosted their price target for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Tempus AI presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

Tempus AI Stock Performance

The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The firm’s fifty day simple moving average is $49.28 and its 200 day simple moving average is $46.70.

Insider Activity at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 187,655 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total value of $7,044,568.70. Following the completion of the transaction, the chief executive officer now owns 9,557,283 shares in the company, valued at $358,780,403.82. This trade represents a 1.93 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total value of $16,999,610.00. Following the sale, the insider now owns 16,164,449 shares in the company, valued at $694,263,084.55. The trade was a 2.39 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 845,041 shares of company stock valued at $35,125,473.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently made changes to their positions in TEM. First Horizon Advisors Inc. acquired a new position in Tempus AI during the third quarter worth $30,000. Geode Capital Management LLC increased its stake in shares of Tempus AI by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after purchasing an additional 539 shares during the last quarter. Vestor Capital LLC bought a new stake in shares of Tempus AI in the 3rd quarter valued at about $153,000. The Manufacturers Life Insurance Company raised its holdings in shares of Tempus AI by 10.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock valued at $1,686,000 after purchasing an additional 2,765 shares during the period. Finally, Stifel Financial Corp acquired a new stake in Tempus AI in the 3rd quarter valued at about $218,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.